share_log

Why Investors Shouldn't Be Surprised By AVITA Medical, Inc.'s (NASDAQ:RCEL) 32% Share Price Plunge

Why Investors Shouldn't Be Surprised By AVITA Medical, Inc.'s (NASDAQ:RCEL) 32% Share Price Plunge

为什么投资者不应该对 AVITA Medical, Inc. 感到惊讶”s(纳斯达克股票代码:RCEL)股价暴跌32%
Simply Wall St ·  2023/10/21 02:19

Unfortunately for some shareholders, the AVITA Medical, Inc. (NASDAQ:RCEL) share price has dived 32% in the last thirty days, prolonging recent pain. Of course, over the longer-term many would still wish they owned shares as the stock's price has soared 114% in the last twelve months.

不幸的是,对于一些股东来说, AVITA Medical, Inc. 纳斯达克股票代码:RCEL)的股价在过去三十天中下跌了32%,延续了最近的痛苦。当然,从长远来看,许多人仍然希望自己拥有股票,因为该股的价格在过去十二个月中飙升了114%。

After such a large drop in price, AVITA Medical may be sending bullish signals at the moment with its price-to-sales (or "P/S") ratio of 6.3x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 10.5x and even P/S higher than 42x are not unusual. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

在价格大幅下跌之后,AVITA Medical目前可能正在发出看涨信号,其市盈率(或 “P/S”)为6.3倍,因为在美国生物技术行业的所有公司中,将近一半的市盈率高于10.5倍,甚至市盈率高于42倍也并不罕见。但是,市盈率低可能是有原因的,需要进一步调查才能确定是否合理。

See our latest analysis for AVITA Medical

查看我们对AVITA Medical的最新分析

ps-multiple-vs-industry
NasdaqCM:RCEL Price to Sales Ratio vs Industry October 20th 2023
纳斯达克证券交易所:RCEL 与行业的比率对比 2023 年 10 月 20 日

How Has AVITA Medical Performed Recently?

AVITA Medical 最近的表现如何?

AVITA Medical certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

AVITA Medical最近确实做得很好,因为它的收入增长幅度超过了大多数其他公司。一种可能性是市盈率很低,因为投资者认为这种强劲的收入表现可能会不那么令人印象深刻。如果你喜欢这家公司,你会希望情况并非如此,这样你就有可能在股票失宠的时候买入一些股票。

Want the full picture on analyst estimates for the company? Then our
想全面了解分析师对公司的估计吗?然后我们的
free
免费的
report on AVITA Medical will help you uncover what's on the horizon.
AVITA Medical的报告将帮助你发现即将发生的事情。

What Are Revenue Growth Metrics Telling Us About The Low P/S?

关于低市盈率,收入增长指标告诉我们什么?

In order to justify its P/S ratio, AVITA Medical would need to produce sluggish growth that's trailing the industry.

为了证明其市盈率是合理的,AVITA Medical需要实现落后于该行业的缓慢增长。

If we review the last year of revenue growth, the company posted a terrific increase of 37%. The strong recent performance means it was also able to grow revenue by 186% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenue over that time.

如果我们回顾一下去年的收入增长,该公司公布了37%的惊人增长。最近的强劲表现意味着它在过去三年中总收入也增长了186%。因此,我们可以首先确认该公司在这段时间内在增加收入方面做得非常出色。

Looking ahead now, revenue is anticipated to climb by 39% each year during the coming three years according to the ten analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 103% per year, which is noticeably more attractive.

关注该公司的十位分析师表示,展望未来,预计未来三年收入将每年增长39%。同时,预计该行业的其他部门每年将增长103%,这明显更具吸引力。

In light of this, it's understandable that AVITA Medical's P/S sits below the majority of other companies. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.

有鉴于此,可以理解的是,AVITA Medical的市盈率低于大多数其他公司。显然,许多股东不愿坚持下去,而该公司可能将目光投向不那么繁荣的未来。

The Bottom Line On AVITA Medical's P/S

AVITA Medical P/S 的底线

The southerly movements of AVITA Medical's shares means its P/S is now sitting at a pretty low level. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

AVITA Medical的股票向南走势意味着其市盈率目前处于相当低的水平。有人认为,在某些行业中,价格与销售比率是衡量价值的次要指标,但它可能是一个有力的商业情绪指标。

As we suspected, our examination of AVITA Medical's analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.

正如我们所怀疑的那样,我们对AVITA Medical分析师预测的审查显示,其收入前景不佳是其低市盈率的原因。在现阶段,投资者认为收入改善的可能性还不够大,不足以证明提高市盈率是合理的。在这种情况下,很难看到股价在不久的将来强劲上涨。

Plus, you should also learn about these 3 warning signs we've spotted with AVITA Medical.

另外,你还应该了解这些 我们在 AVITA Medical 上发现了 3 个警告信号

If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

如果实力雄厚的公司让你大开眼界,那么你一定要看看这个 免费的 以低市盈率交易(但已证明可以增加收益)的有趣公司名单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发